Sette G, Baron J C, Young A R, Miyazawa H, Tillet I, Barré L, Travère J M, Derlon J M, MacKenzie E T
Centre Cyceron, INSERUM U.320, CNRS ERS 019, CEA DSV/DPTE, University of Caen, France.
Stroke. 1993 Dec;24(12):2046-57; discussion 2057-8. doi: 10.1161/01.str.24.12.2046.
Recent reports have shown an increase in specific binding (in vitro) of [3H]PK 11195 to peripheral-type benzodiazepine receptors in both experimental animals and humans, reflecting a glial/macrophagic reaction within and around focal ischemic insults. We have evaluated by positron emission tomography the time course of changes in brain uptake in vivo of 11C-labeled PK 11195 and flumazenil (an antagonist of central benzodiazepine receptors) as indirect and direct markers of neuronal loss, respectively, after focal cerebral ischemia.
Ten anesthetized baboons were submitted to sequential positron emission tomography studies between day 1 and day 91 after unilateral middle cerebral artery occlusion. The studies consisted of successive assessments, in the same positron emission tomography session, of [11C]PK 11195, [11C]flumazenil, cerebral blood flow, and oxygen consumption; late computed tomographic scans were obtained to map the approximate contours of infarction and to define a concentric peri-infarct area.
We found a significant time-dependent increase in [11C]PK 11195 uptake in the peri-infarcted area, maximum at 20 to 40 days after occlusion. In contrast, there was a time- and perfusion-independent significant decrease in [11C]flumazenil uptake in the infarcted area, stable from day 2 onward, and already present in one baboon at day 1. Challenge studies with saturating doses of cold ligands confirmed that these changes represented alterations in specific binding. [11C]Flumazenil uptake was not affected in hypometabolic (but apparently noninfarcted, ie, deafferented) cortical areas.
The delayed and apparently transient increases in [11C]PK 11195 specific uptake in vivo presumably represent glial/macrophage reaction; the marked depression in [11C]flumazenil specific binding, which appears selective for synaptic damage, is both precocious and sustained and thus may be better suited for the early assessment of ischemic damage in humans.
最近的报告显示,在实验动物和人类中,[3H]PK 11195与外周型苯二氮䓬受体的特异性结合(体外)均有所增加,这反映了局灶性缺血性损伤内部及周围的胶质/巨噬细胞反应。我们通过正电子发射断层扫描评估了局灶性脑缺血后,11C标记的PK 11195和氟马西尼(一种中枢苯二氮䓬受体拮抗剂)在体内脑摄取变化的时间进程,分别作为神经元丢失的间接和直接标志物。
10只麻醉的狒狒在单侧大脑中动脉闭塞后第1天至第91天接受了连续的正电子发射断层扫描研究。这些研究包括在同一正电子发射断层扫描时段内,对[11C]PK 11195、[11C]氟马西尼、脑血流量和氧耗进行连续评估;后期进行计算机断层扫描以描绘梗死的大致轮廓并确定梗死周围的同心区域。
我们发现梗死周围区域[11C]PK 11195摄取量随时间显著增加,在闭塞后20至40天达到最大值。相比之下,梗死区域[11C]氟马西尼摄取量出现了与时间和灌注无关的显著下降,从第2天起保持稳定,并且在第1天就已在一只狒狒中出现。用饱和剂量的冷配体进行的激发研究证实,这些变化代表了特异性结合的改变。[11C]氟马西尼摄取在代谢减退(但显然未梗死,即去传入)的皮质区域未受影响。
体内[11C]PK 11195特异性摄取的延迟且明显短暂的增加可能代表胶质/巨噬细胞反应;[11C]氟马西尼特异性结合的显著降低对突触损伤具有选择性,既早熟又持续,因此可能更适合于人类缺血性损伤的早期评估。